Related Experiment Video
Updated: May 18, 2026
08:50
Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Novel microfluidic platform for automated lab-on-chip testing of hypercoagulability panel
Sirisha Emani1, Ramakrishna Sista, Hugo Loyola
1Department of Cardiac Surgery, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA. sitaram.emani@cardio.chboston.org
Summary
This study introduces a novel microfluidic platform for rapid hypercoagulability panel testing using a single blood droplet. The technology enables automated, multiplexed testing with high accuracy, potentially improving point-of-care diagnostics.
Area of Science:
- Biotechnology
- Medical Diagnostics
- Microfluidics
Background:
- Current hypercoagulability panel testing demands large blood volumes and extended turnaround times.
- These limitations hinder timely diagnosis and patient management.
Purpose of the Study:
- To evaluate a novel microfluidic platform for automated, multiplexed hypercoagulability panel testing.
- To assess the platform's feasibility for near-patient testing using minimal blood samples.
Main Methods:
- A microfluidic platform was developed for multiplexed ELISA-based testing of hypercoagulability markers (antithrombin III, protein C, protein S, factor VIII) and antibodies.
- Magnetic beads and fluorescence readout were employed for sandwich ELISA.
- On-chip assays were compared with traditional bench-top methods using patient blood samples.
Main Results:
- The platform successfully performed multiplexed hypercoagulability panel testing in 72 minutes.
- Recovery rates (80-120%) were consistent between single-factor and multiplex assays.
- On-chip assay results showed no significant difference compared to traditional bench-top assays.
Conclusions:
- The novel digital microfluidic platform enables high-fidelity, automated hypercoagulability panel testing on small blood volumes.
- This technology shows promise for point-of-care clinical applications.
- Further validation is needed for widespread clinical adoption.
